Phosphatidylcholine — The Cellular Membrane Foundation
Phosphatidylcholine (PC) is the most abundant phospholipid in mammalian cell membranes, playing a critical role in maintaining membrane fluidity, cellular signaling, and lipid transport. In the context of longevity, PC supplementation aims to counteract age-related declines in membrane integrity and support hepatic and cognitive function.
Mechanism of Action
PC is a major structural component of cellular membranes and a precursor to the neurotransmitter acetylcholine. It is synthesized primarily via the CDP-choline (Kennedy) pathway or by methylation of phosphatidylethanolamine (PEMT pathway). PC facilitates the export of triglycerides from the liver via very-low-density lipoproteins (VLDL), preventing hepatic steatosis. Additionally, it provides choline for acetylcholine synthesis, supporting cholinergic neurotransmission, and acts as a source of signaling molecules like diacylglycerol (DAG) and phosphatidic acid.
Human Trial Evidence
Human trials have primarily focused on PC's efficacy in liver disease and cognitive decline. Clinical studies demonstrate that polyenylphosphatidylcholine (PPC) can improve liver enzyme profiles and histology in patients with non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease. Evidence for cognitive enhancement or systemic longevity in healthy aging humans remains limited, though some trials suggest mild benefits in early-stage dementia.
Dosing Protocol
Typical oral dosing ranges from 900 mg to 2,700 mg per day, often divided into two or three doses with meals. Intravenous administration (e.g., Plaquex therapy) is used in some clinical settings for cardiovascular and hepatic indications, though protocols vary widely and lack standardized longevity guidelines.
Safety & Contraindications
Generally well-tolerated at standard doses. Potential adverse effects include gastrointestinal distress, nausea, and diarrhea. A theoretical concern is the conversion of unabsorbed dietary choline to trimethylamine (TMA) by gut bacteria, which is oxidized in the liver to trimethylamine N-oxide (TMAO), a compound associated with increased cardiovascular risk.